Rituximab (RTX), an anti-CD20 monoclonal antibody used in treatment of hematologic and rheumatologic disease, depletes systemic and intestinal B-cells. Diarrhea is seen in ∼15% of people. Case reports associated RTX with de novo inflammatory bowel disease (IBD). We aim to characterize clinical features and course of RTX-induced colitis.